Dopamine modulation of oxytocin prosocial effects

INTERVENTION: Trade Name: Syntocinon nasal Spray Pharmaceutical Form: Nasal spray INN or Proposed INN: OXYTOCIN CAS Number: 50‐56‐6 Concentration unit: U unit(s) Concentration type: equal Concentration number: 40‐ Pharmaceutical form of the placebo: Nasal spray Route of administration of the placebo: Nasal use CONDITION: HEALTHY VOLUNTEERS. FOR PATIENTS WITH AUTISM OR SCHIZOPHRENIA Therapeutic area: Psychiatry and Psychology [F] ‐ Behaviours [F01] PRIMARY OUTCOME: Main Objective: Characterize dopaminergic D2 system modulation on prosocial responses to oxytocin Primary end point(s): Cerebral and social behavior responses to intranasal oxytocin administration in genetic variants of D2 system Secondary Objective: Multimodal identification of cerebral responses associated with oxytocin Timepoint(s) of evaluation of this end point: 3 years SECONDARY OUTCOME: Secondary end point(s): Cerebral and social behavior responses to intranasal oxytocin administration in genetic variants of D2 system Timepoint(s) of evaluation of this end point: 3 years INCLUSION CRITERIA: Male Caucasian, healthy subjects (age: 18‐44 years) with negative history of neurological, medical and psychiatric diseases. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range